Advice
Strontium ranelate discontinued
In August 2017, due to limited demand, attributed to restrictions on its indication and additional monitoring requirements that followed a review by the European Medicines Agency of the risks and benefits of treatment, Les Laboratoires Servier, ceased the distribution of strontium ranelate (Protelos), for the treatment of osteoporosis in men at increased risk of fracture.
Medicine details
- Medicine name:
- strontium ranelate (Protelos)
- SMC ID:
- 816/12
- Indication:
- Treatment of osteoporosis in men at increased risk of fracture.
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Withdrawn
- Date advice published
- 08 October 2012